Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 18/20 | 1.00 |
| ▸ | DRD3 | P35462 | 15/20 | 1.00 |
| ▸ | DRD2 | P14416 | 14/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 1/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | HTR2C | P28335 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | HRH1 | P35367 | 1/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 1/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nemonapride SCHEMBL25247691 | 1.00 | DRD4 (1.00) | DRD4DRD3DRD2NR1I2ADRB2 | |
| Nemonapride SCHEMBL30442102 | 1.00 | DRD4 (1.00) | DRD4DRD3DRD2NR1I2ADRB2 | |
| Nemonapride SCHEMBL1649724 | 1.00 | DRD4 (1.00) | DRD4DRD3DRD2NR1I2ADRB2 | |
| Nemonapride SCHEMBL50208 | 1.00 | DRD4 (1.00) | DRD4DRD3DRD2NR1I2ADRB2 | |
| Nemonapride SCHEMBL29387146 | 1.00 | DRD4 (1.00) | DRD4DRD3DRD2NR1I2ADRB2 | |
| Nemonapride SCHEMBL11462830 | 0.99 | DRD4 (0.98) | DRD4DRD3DRD2NR1I2ADRB2 | |
| Nemonapride SCHEMBL8824385 | 0.99 | DRD4 (0.98) | DRD4DRD3DRD2NR1I2ADRB2 | |
| Nemonapride SCHEMBL31320714 | 0.94 | DRD4 (0.88) | DRD4DRD3DRD2NR1I2ADRB2 | |
| Nemonapride SCHEMBL31320727 | 0.88 | DRD4 (0.79) | DRD4DRD3DRD2NR1I2ADRB2 | |
| Nemonapride SCHEMBL31427577 | 0.88 | DRD4 (0.78) | DRD4DRD3DRD2NR1I2ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1685 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12527754-B2 | Methods and compositions for preventing and treating metabolic syndrome induced by antipsychotic treatment and related diseases and conditions | TUFTS MEDICAL CENTER, INC. (US) | 2026-01-20 | — | — | US | claimed |
| EP-4674482-A2 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS ASSOCIATED WITH NEURODEGENERATIVE DISEASE OR IMPULSIVE SYMPTOMS ASSOCIATED WITH MENTAL DISEASE CONTAINING BREXPIPRAZOLE OR SALT THEREOF | Otsuka Pharmaceutical Co., Ltd. (JP) | 2026-01-07 | — | — | EP | claimed |
| US-20250367212-A1 | PHARMACOTHERAPY FOR OBSESSIVE-COMPULSIVE DISORDER TARGETING DOPAMINE D1 SIGNAL IN STRIATAL STRIOSOMES | MATSUMOTO SHINICHI (JP) | 2025-12-04 | — | — | US | claimed |
| EP-4618973-A1 | METHODS OF SWITCHING NEUROPSYCHIATRIC MEDICATIONS USING ULOTARONT | Sumitomo Pharma America, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| WO-2025101418-A1 | TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS IN PATIENTS WITH PROMINENT ANHEDONIA USING IRDABISANT AS A MONOTHERAPY OR IN COMBINATION WITH AN ANTIPSYCHOTIC AGENT | ALTO NEUROSCIENCE, INC. (US) | 2025-05-15 | — | — | WO | claimed |
| US-20250144092-A1 | TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS IN PATIENTS WITH PROMINENT ANHEDONIA USING IRDABISANT AS A MONOTHERAPY OR IN COMBINATION WITH AN ANTIPSYCHOTIC AGENT | ALTO NEUROSCIENCE, INC. | 2025-05-08 | — | — | US | claimed |
| EP-4541372-A1 | DRUG THERAPY FOR OBSESSIVE-COMPULSIVE DISORDER TARGETING DOPAMINE D1 SIGNAL IN STRIATAL STRIOSOMES | Matsumoto, Shinichi (JP) | 2025-04-23 | — | — | EP | claimed |
| US-20250099459-A1 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS ASSOCIATED WITH NEURODEGENERATIVE DISEASE OR IMPULSIVE SYMPTOMS ASSOCIATED WITH MENTAL DISEASE CONTAINING BREXPIPRAZOLE OR SALT THEREOF | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2025-03-27 | — | — | US | claimed |
| WO-2024107681-A1 | METHODS OF SWITCHING NEUROPSYCHIATRIC MEDICATIONS USING ULOTARONT | SUMITOMO PHARMA AMERICA, INC. (US) | 2024-05-23 | — | — | WO | claimed |
| WO-2023243659-A1 | DRUG THERAPY FOR OBSESSIVE-COMPULSIVE DISORDER TARGETING DOPAMINE D1 SIGNAL IN STRIATAL STRIOSOMES | 松本 真一 | 2023-12-21 | — | — | WO | claimed |
| WO-2003026563-A9 | CONJUGATED ANTI-PSYCHOTIC DRUGS AND USES THEREOF | UNIV RAMOT (IL) | 2004-04-22 | — | — | WO | claimed |
| EP-1404342-A1 | TREATMENT OF PSYCHOTIC DISORDERS COMPRISING CO-THERAPY WITH ANTICONVULSANT DERIVATIVES AND ATYPICAL ANTIPSYCHOTICS | Ortho-Mcneil Pharmaceutical, Inc. (US) | 2004-04-07 | — | — | EP | claimed |
| US-20030109546-A1 | Treatment of psychotic disorders comprising co-therapy with anticonvulsant derivatives and atypical antipsychotics | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-06-12 | — | — | US | claimed |
| WO-2003026563-A2 | CONJUGATED ANTI-PSYCHOTIC DRUGS AND USES THEREOF | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2003-04-03 | — | — | WO | claimed |
| EP-1273301-A2 | Pharmaceutical preparations based on active ingredients susceptible to illicit administration | ALTERGON S.A. (CH) | 2003-01-08 | — | — | EP | claimed |
| WO-2002087590-A1 | TREATMENT OF PSYCHOTIC DISORDERS COMPRISING CO-THERAPY WITH ANTICONVULSANT DERIVATIVES AND ATYPICAL ANTIPSYCHOTICS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2002-11-07 | — | — | WO | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| US-5624687-A | Quick-dissolution solid preparation | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1997-04-29 | — | — | US | claimed |
| EP-0580862-A1 | RAPIDLY SOLUBLE SOLID PREPARATION | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1994-02-02 | — | — | EP | claimed |
| US-4210660-A | CENTRAL NERVOUS SYSTEM DEPRESSANTS, ESPECIALLY ANTIPSYCOTICS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1980-07-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109546-A1 | Treatment of psychotic disorders comprising co-therapy with anticonvulsant derivatives and atypical antipsychotics | GABRE, GABRQ, GABRA4 | DRD4 36/4885DRD3 72/4885DRD2 33/4885 |
| US-12527754-B2 | Methods and compositions for preventing and treating metabolic syndrome induced by antipsychotic treatment and related diseases and conditions | GPR119, TPH1, LIPC | DRD4 573/4885DRD3 338/4885DRD2 318/4885 |
| US-20250099459-A1 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS ASSOCIATED WITH NEURODEGENERATIVE DISEASE OR IMPULSIVE SYMPTOMS ASSOCIATED WITH MENTAL DISEASE CONTAINING BREXPIPRAZOLE OR SALT THEREOF | SLC6A3, SLC6A2, SNCA | DRD4 107/4885DRD3 208/4885DRD2 96/4885 |
| US-20250144092-A1 | TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS IN PATIENTS WITH PROMINENT ANHEDONIA USING IRDABISANT AS A MONOTHERAPY OR IN COMBINATION WITH AN ANTIPSYCHOTIC AGENT | GRIN2B, DRD2, SLC6A3 | DRD4 13/4885DRD3 11/4885DRD2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.